Bayer's $2.9bn bid wins Norway cancer firm
The Local/AFP - [email protected]
Published: 19 Dec, 2013 CET.
Updated: Thu 19 Dec 2013 12:38 CET
Norwegian cancer treatment specialist Algeta has agreed to a 1.9 billion euro ($2.9bn) takeover from Germany's Bayer, after the pharmaceuticals giant sweetened its bid, offering 363 kroner per share in cash.
"The Bayer group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta," the German group said in a statement. "Bayer has reached an agreement with Algeta's board of directors to make a recommended voluntary public takeover offer to Algeta's shareholders, and is offering them 362 kronor per share in cash," the statement added. The offer implied an equity value of 17.6 billion kronor, or 2.1 billion euros, and an enterprise value of 16.2 billion kronor or 1.9 billion euros. The offer price represented a premium of 37 percent over the closing price on November 25, the day before Algeta confirmed that it had received a preliminary, non-binding acquisition proposal from Bayer. Bayer said Algeta's board of directors had "unanimously decided to recommend acceptance of the offer to its shareholders." "We have already successfully collaborated with Algeta to develop and commercialize the cancer drug Xofigo. The planned acquisition would give us full control over Xofigo. We are absolutely convinced of the potential of this drug," said Bayer chief executive Marijn Dekkers.
Comments
See Also
"The Bayer group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta," the German group said in a statement.
"Bayer has reached an agreement with Algeta's board of directors to make a recommended voluntary public takeover offer to Algeta's shareholders, and is
offering them 362 kronor per share in cash," the statement added.
The offer implied an equity value of 17.6 billion kronor, or 2.1 billion euros, and an enterprise value of 16.2 billion kronor or 1.9 billion euros.
The offer price represented a premium of 37 percent over the closing price on November 25, the day before Algeta confirmed that it had received a preliminary, non-binding acquisition proposal from Bayer.
Bayer said Algeta's board of directors had "unanimously decided to recommend acceptance of the offer to its shareholders."
"We have already successfully collaborated with Algeta to develop and commercialize the cancer drug Xofigo. The planned acquisition would give us full control over Xofigo. We are absolutely convinced of the potential of this drug," said Bayer chief executive Marijn Dekkers.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.